KdT promotes Grayeski, Malone as firm unveils new fund

KdT Ventures promoted Phil Grayeski to managing partner from partner and Patrick Malone to partner from principal. The changes accompany the close of the firm’s $100 million Fund IV, its largest to date, which KdT will deploy in early-stage companies working in areas such as therapeutics, digital health, industrial biotechnology and climate. 

Kathleen Sereda Glaub has become CEO of  CuraSen Therapeutics Inc., which is developing small molecules to treat psychiatric and neurodegenerative diseases. Glaub, who was CuraSen’s executive chair, succeeds co-founder Anthony Ford, who is now president and CSO, with Patrick Enright becoming chair. Enright is a managing director of Longitude Capital, which contributed to CuraSen’s series A. ...